glp-1 news today receptor agonists show promise in treating substance use disorders GLP-1 Pipeline Update: May 2025

For a full breakdown of costs and insurance coverage, see what is GLP-1

Safety Considerations for Combining Weight Loss and Antidepressant Therapy Blood pressure monitoring becomes especially important when using semaglutide and bupropion together, since bupropion can moderately elevate systolic and diastolic readings in some patients

Important safety considerations include the risk of pancreatitis (all GLP-1 agonists carry warnings about this), gallbladder disease (more common with greater weight loss), and a caution with semaglutide in patients with pre-existing diabetic retinopathy, where rapid improvement in glucose control may temporarily worsen retinopathy

Patients who experience rapid dose escalation may be more prone to fatigue and gastrointestinal symptoms

One self-pay platform

doi:10.1016/0165-2478(94)00230-O 59